Patents by Inventor Mingyu Shi

Mingyu Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11994603
    Abstract: A method of sparse array oriented approach for DOA estimation of grating lobe target filtering includes sub-array division processing of received echoes in multiple channels; digital beamforming is performed on each sub-array obtained after division to realize DOA estimation; the echo power of the beam pointing at each angle is calculated and the peak point is detected; peak threshold discrimination processing is performed based on the determined peak threshold; if the current sub-array satisfies the identified peak threshold, the corresponding power spectrum extreme is calculated to obtain the final DOA estimation. The present invention also relates to a corresponding device, processor and computer-readable storage medium thereof.
    Type: Grant
    Filed: October 18, 2023
    Date of Patent: May 28, 2024
    Assignee: SHANGHAI GEOMETRICAL PERCEPTION AND LEARNING CO., LTD.
    Inventors: Yue Zhao, Mingyu Zhou, Songhua Shi, Dan Xue
  • Patent number: 8227612
    Abstract: The present invention discloses a quinoline compound represented by the formula A or pharmaceutically acceptable solvate, optical isomer or polymorph thereof, wherein X is S or O; M is H, Na+, NH4+ or Ca2+; each of R1, R2 and R3 is independently H, halogen, the group represented by formula D or formula E; R is H, halogen, C1˜C4 alkyl or C1˜C4 alkoxy. The present invention also discloses its pharmaceutical composition and the preparation method thereof and application in manufacturing a medicament for inhibiting HMG-CoA reductase or for the treatment and prophylaxis of the diseases which can be treated effectively by inhibiting HMG-CoA reductase. The quinloline compound and pharmaceutical composition thereof of the present invention have an excellent lipid reduction effect in vivo and can be applied for treatment of a hyperlipidemia-related disease.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: July 24, 2012
    Assignee: Shanghai Institute of Pharmaceutical Industry
    Inventors: Zhengyan Cai, Weicheng Zhou, Qun Hao, Zhenhua Shi, Yuchen Sheng, Mingyu Shi, Qingning Liang
  • Publication number: 20110021561
    Abstract: The present invention discloses a quinoline compound represented by the formula A or pharmaceutically acceptable solvate, optical isomer or polymorph thereof, wherein X is S or O; M is H, Na+, NH4+ or Ca2+; each of R1, R2 and R3 is independently H, halogen, the group represented by formula D or formula E; R is H, halogen, C1˜C4 alkyl or C1˜C4 alkoxy. The present invention also discloses its pharmaceutical composition and the preparation method thereof and application in manufacturing a medicament for inhibiting HMG-CoA reductase or for the treatment and prophylaxis of the diseases which can be treated effectively by inhibiting HMG-CoA reductase. The quinloline compound and pharmaceutical composition thereof of the present invention have an excellent lipid reduction effect in vivo and can be applied for treatment of a hyperlipidemia-related disease.
    Type: Application
    Filed: April 29, 2009
    Publication date: January 27, 2011
    Inventors: Zhengyan Cai, Weicheng Zhou, Qun Hao, Zhenhua Shi, Yuchen Sheng, Mingyu Shi, Qingning Liang